Reported 1 day ago
Piper Sandler analyst Yasmeen Rahimi has maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) with a price target of $107 effective June 4. Despite a recent downgrade by JPMorgan, the firm continues to view aficamten, a drug for obstructive hypertrophic cardiomyopathy, as having strong potential due to its unique profile compared to competitors. Cytokinetics focuses on developing muscle inhibitors aimed at improving muscle function.
Source: YAHOO